VistaGen Therapeutics (NASDAQ:VTGN) Issues Earnings Results

VistaGen Therapeutics (NASDAQ:VTGN) issued its quarterly earnings data on Thursday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06, Zacks reports. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million.

Here are the key takeaways from VistaGen Therapeutics’ conference call:

• The company completed the randomized portion of PALISADE‑3 and found a higher placebo response versus earlier studies, prompting further analysis and adjustments.
• Enrollment for PALISADE‑4 remains on track and the company has implemented site retraining, site rationalization, centralized recruitment and operational controls (including audio monitoring) to mitigate placebo effects.
• Vistagen is partnering with third‑party AI/ML collaborators to analyze PALISADE data for covariates and predictors of response and may seek to modify the statistical analysis plan if justified—any SAP change would require FDA resubmission and alignment.
• In women’s health, PH80 received the USAN name rafisolone and Vistagen plans to file a US IND in the first half of 2026 to support potential Phase 2 development for vasomotor symptoms, building on a prior Phase 2A signal.
• Financially, Vistagen reported approximately $61.8 million in cash and has implemented companywide cash‑preservation measures, which management says positions them to complete PALISADE‑4 and advance pipeline planning.

VistaGen Therapeutics Price Performance

VTGN stock opened at $0.51 on Friday. The firm has a market cap of $19.97 million, a price-to-earnings ratio of -0.27 and a beta of 0.32. VistaGen Therapeutics has a 1-year low of $0.43 and a 1-year high of $5.14. The firm has a fifty day moving average price of $1.17 and a two-hundred day moving average price of $2.81.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VTGN. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research note on Wednesday, December 17th. Wall Street Zen raised shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Jefferies Financial Group reissued a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $0.95.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new position in VistaGen Therapeutics in the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of VistaGen Therapeutics during the 3rd quarter worth approximately $39,000. Bank of America Corp DE raised its position in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the period. Marshall Wace LLP bought a new stake in shares of VistaGen Therapeutics in the 2nd quarter worth approximately $69,000. Finally, Millennium Management LLC acquired a new position in VistaGen Therapeutics during the 3rd quarter valued at approximately $73,000. Institutional investors own 78.39% of the company’s stock.

Key Headlines Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Q3 results beat consensus on both EPS and revenue (reported loss $0.45/sh vs. est. $0.51; revenue $0.30M vs. est. $0.14M), which is supportive for the stock as it shows slightly better-than-expected financial performance. Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results
• Neutral Sentiment: Management provided a corporate update saying it reviewed PALISADE-3 data and implemented “moderate refinements,” language that is ambiguous for program outlook until full details from the company/meeting are disclosed; investors will look to the earnings call/transcript for color. Earnings Press Release / Call Materials Q3 2026 Earnings Call Transcript
• Negative Sentiment: A large cluster of investor alerts and class-action solicitations from multiple law firms (Robbins LLP, Schall Law Firm, Rosen, Pomerantz, DJS, Bernstein Liebhard, Gross, etc.) allege Vistagen misled investors about trial viability and seek lead plaintiffs — this increases legal overhang, raises potential litigation costs, and is the most likely proximate cause of downward pressure on the stock. Representative notices: Robbins LLP Notice Schall Law Firm Notice DJS Law Group Notice

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.